Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Braun, Michael S
Saunders, Mark P
AffiliationDepartment of Medical/Clinical Oncology, Christie Hospital, 550 Wilmslow Road, Manchester, UK
MetadataShow full item record
AbstractCutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.
CitationManagement and grading of EGFR inhibitor-induced cutaneous toxicity. 2018 Future Oncol
- HLA-C*15:02 and epidermal growth factor receptor inhibitor-induced erosive pustular dermatosis of the scalp.
- Authors: Zhang Y, Grice S, Wang N, Liu Y, Zhao Q, Liu T, Sun L, Mi Z, Wang J, Yu G, Zhang F, Meng X, Liu H, Naisbitt DJ, Sun Y, Zhang F
- Issue date: 2023 Oct 25